Back HIV/AIDS

HIV / AIDS

IAS 2013: Middle-income Countries Outside Africa Pay Four Times More for Antiretroviral Drugs

Middle-income countries outside Africa are paying, on average, 4 times more for antiretrovirals than African countries with similar gross national incomes (GNI), according to a study presented recently at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur.

alt

[Produced in collaboration with Aidsmap.com]

HIV+ Women May Experience More Severe Menopause Symptoms

Women with HIV on average experience more severe hot flashes around the time of menopause than HIV negative women, and they interfere more with daily life, according to a study described in the July 1, 2013, advance online edition of the journal Menopause.

alt

IAS 2013: Meta-analysis Finds Early HIV Treatment Reduces Risk of AIDS and Death

A meta-analysis of more than 30 studies found that starting antiretroviral therapy with a CD4 T-cell count above 350 cell/mm3 was associated with a lower risk of progression to AIDS or death, according to a poster presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.

alt

IAS 2013: Cost of HIV Drugs in Resource-limited Settings [VIDEO]

The price of first- and second-line antiretroviral medications has fallen in recent years, largely due to increased competition among generic drug producers, but the newest antiretrovirals continue to be priced out of reach of many who need them, according to a report released by Médecins Sans Frontières/Doctors Without Borders to coincide with the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Changes in Gut Bacteria May Promote Inflammation and HIV Disease Progression

Changes in intestinal bacteria may contribute to disease progression and development of non-AIDS conditions in people with HIV, even those on effective antiretroviral therapy (ART), according to a report in the July 10, 2013, issue of Science Translational Medicine.

alt

IAS 2013: Stribild 'Quad' Pill Continues to Show Good Efficacy at 96 Weeks

The 4-in-1 Stribild single-tablet regimen maintains HIV viral load suppression through 96 weeks and remains generally well-tolerated, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur. Another study found that Stribild and its component cobicistat appear safe for people with mild-to-moderate kidney impairment.

alt

IAS 2013: Intensive ART During Primary HIV Infection Lowers Viral Reservoir

Starting intensive antiretroviral therapy (ART) with a 5-drug regimen during the earliest stages of HIV infection can result in lower levels of virus in resting T-cell reservoirs, leading to improved immune function and potentially a better chance at a functional cure, according to studies presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.

alt